Synapse - Works

Results (2639)

Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study

Meeting Abstract

Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; more...
Blood (2023)

Fulltext@MSK | Save

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed / refractory marginal zone lymphoma: Results from phase 1/2 BRUIN study

Meeting Abstract

Patel, K.; Vose, J. M.; Nasta, S. D.; Brown, J. R.; Maddocks, K. J.; Woyach, J. A.; Shah, N. N.; Fakhri, B.; Tessoulin, B.; Ma, S.; more...
Blood (2023)

Fulltext@MSK | Save

TRANSCEND FL: Phase 2 study primary analysis of lisocabtagene maraleucel as second-line therapy in patients with high-risk relapsed or refractory follicular lymphoma

Meeting Abstract

Morschhauser, F.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Reguera, J. L.; Kuruvilla, J.; Jaeger, U.; Cartron, G.; Izutsu, K.; Dreyling, M.; more...
Blood (2023)

Fulltext@MSK | Save

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma (SGN35-027 Part C)

Meeting Abstract

Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S. R.; Linhares, Y.; Ramchandren, R.; more...
Blood (2023)

Fulltext@MSK | Save

Efficacy and safety of valemetostat monotherapy in patients with relapsed or refractory peripheral T-cell lymphomas: Primary results of the phase 2 VALENTINE-PTCL01 study

Meeting Abstract

Horwitz, S. M.; Izutsu, K.; Mehta-Shah, N.; Cordoba, R.; Barta, S. K.; Bachy, E.; Gritti, G.; Jacobsen, E.; Kusumoto, S.; Guillermin, Y.; more...
Blood (2023)

Fulltext@MSK | Save

Multicenter, real-world study in patients with R/R large B- cell lymphoma (LBCL) who received lisocabtagene maraleucel (liso-cel) in the United States (US)

Meeting Abstract

Crombie, J. L.; Nastoupil, L. J.; Andreadis, C.; Isufi, I.; Hunter, B.; Winter, A.; Hess, B.; Barta, S. K.; Frigault, M. J.; Palomba, M. L.; more...
Blood (2023)

Fulltext@MSK | Save

Valemetostat for relapsed or refractory peripheral T-cell lymphomas: Primary results from a phase 1 trial

Meeting Abstract

Jacobsen, E.; Maruyama, D.; Porcu, P.; Tobinai, K.; Allen, P. B.; Ishitsuka, K.; Tsukasaki, K.; Kusumoto, S.; Foss, F. M.; Yamauchi, N.; more...
Blood (2023)

Fulltext@MSK | Save

Response to mosunetuzumab in patients with B-cell lymphomas relapsed or refractory after CAR-T cell therapy is associated with changes in lymphocyte counts

Meeting Abstract

Chong, E. A.; Penuel, E.; Bartlett, N. L.; Bosch, F.; Budde, L. E.; Fay, K.; Flinn, I. W.; Goy, A.; Kumar, A.; Lundberg, R.; more...
Blood (2023)

Fulltext@MSK | Save

Novel causal inference method estimates treatment effects of contemporary drugs in a global cohort of patients with relapsed and refractory mature T-cell and NK-cell neoplasms

Meeting Abstract

Koh, M. J.; Boussi, L.; Han, J. X.; Peng, L.; Sorial, M. N.; Eche-Ugwu, I. J.; Miranda, E.; Chiattone, C.; Stuver, R.; Horwitz, S. M.; more...
Blood (2023)

Fulltext@MSK | Save

Early results indicate acceptable safety and promising efficacy of venetoclax in combination with pola-R-CHP for untreated high-risk BCL-2-positive B-cell lymphoma including double/triple hit lymphoma

Meeting Abstract

Zelenetz, A. D.; Diefenbach, C. S.; Herbaux, C.; Tani, M.; Houot, R.; Bastos-Oreiro, M.; Tilly, H.; Gastinne, T.; Thieblemont, C.; Troy-Barnes, E.; more...
Blood (2023)

Fulltext@MSK | Save